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Single-aerosol inhalerInternational guidelines describe asthma control as themain outcomeof asthmamanagement. Preventionof symp-
toms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing
health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large
proportion of asthmatic patients are not well controlled despite the efﬁcacy of current available treatment.
Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-
agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicen-
ter phase III clinical studies demonstrate that theﬁxed combination of ﬂuticasone propionate/formoterol in a sin-
gle inhaler is effective in terms of lung function and symptom control. These studies highlight the dose ﬂexibility,
safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of inter-
national guidelines, and the preferences of respiratory physicians who identiﬁed these aspects as critical compo-
nents of a successful asthma therapy. Combination of ﬂuticasone propionate/formoterol in a single inhaler
provides potent anti-inﬂammatory activity of ﬂuticasone propionate and rapid onset of action of the β2-agonist
formoterol making this association a viable treatment option both in terms of effectiveness and compliance.
© 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. IntroductionAsthma affects about 300 million people of all ages and ethnic
groups worldwide [1], with an estimated increase in prevalence to
400 million by 2025 [2]. The economic burden in terms of direct (hospi-
talization, use of emergency room visits, therapy) and indirect (missed
days of work/school) costs adds to the emotional, physical and social
impact of asthma, with consequent quality of life deterioration for
both patients and their families [3]. Despite the availability of effective
treatments, a large proportion of asthma patients experience symptoms
of uncontrolled asthma, even in those geographical areas where good
standards of care are available [2,4–8].icine and Research Center on
ari di San Rocco, 27, 44121
10297.
cine. Published by Elsevier B.V. All rigIn the AIRE (Asthma Insights and Reality in Europe) study, involving
over 2800 patients from different European countries, more than
half of the patients reported daytime asthma symptoms and a third
complained of asthma-related sleep disturbances [9]. The INSPIRE (Inter-
national AsthmaPatient Insight Research) study,where 3415 adults treat-
ed for asthmawere interviewed, reported daily use of rescue short-acting
bronchodilator in almost 74% of the patients, while 51% had experienced
at least one exacerbation in the previous year [7]. More recently, in 2006,
2008 and 2010, the results of three surveys in patients fromﬁve European
countries (France, Germany, Italy, Spain and United Kingdom) revealed
that 50% or more of asthma patients reported suboptimal symptom
multi-dose DPIscontrol [5,10,11].2. Potential causes of inadequate asthma control
Among the possible causes of impaired asthma control, the hetero-
geneity of the disease, the continued exposure to irritants or triggers,hts reserved.
Table 1
Expert panel agreement⁎ on the characteristics of an effective ICS/LABA combination
therapy. The results refer to the ﬁnal round of a Delphi process [29].
Treatment attribute Percentage of agreement
Dosage ﬂexibility 88%
ICS: long term safety and tolerability 81%
LABA: long term safety and tolerability 81%
Efﬁcacy (asthma control) 81%
ICS: anti-inﬂammatory effect 69%
LABA: speed of onset 69%
ICS, inhaled corticosteroid; LABA, long-acting inhaled β2-agonist.
⁎ Agreement = consensus in a percentage of experts ≥66%.
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ence to treatment [13] should be considered. In the last years some
greater attention has been put in the diagnosis and management of co-
morbidities and triggers. By contrast, non-adherence to medications
remains very common in asthma, perhaps more than in other chronic
diseases. Indeed, there is evidence to indicate that a combination of
suboptimal use of available drugs, poor adherence to treatment
and misjudgment of the level of asthma control by physicians and/or
patients, contributes to unsuccessful disease control. Possibly this is
also due to poor inhaler technique, a variety of unintentional non-
adherence, which is widespread and neglected in asthma [14]. Two
main types of inhaler devices are currently available for drug lungdelivery
in asthma,metered dose inhalers (MDIs) and dry powder inhalers (DPIs).
Importantly, the issue of inhalermisusewas ﬁrstly recognizedwithMDIs,
as the diffusion of DPIs is relatively recent. However, it is currently known
that inhalermisuse is commonwith bothMDIs andDPIs and is associated
with poor asthma control with both devices [15]. Although it is increas-
ingly believed that a careful choice of themost appropriate inhaler device,
in accordance with the patient, can certainly improve patient's satisfac-
tion, adherence and clinical outcomes, guidelines do not give a clear indi-
cation about the best device. In fact, it is accepted that different devices
are clinically equivalent with regard to safety and efﬁcacy when they
are used to deliver the same drug at equipotent doses [16]. Similarly,
there is no clear evidence for a preference between inhaler devices [17].
However, simplifying the regimen schedule, by including the use of a sin-
gle inhaler with different drug combinations, or using the same type of
device when different drugs are required, or the addition of bronchodila-
torswith fast onset of actionmay improve asthma adherence and control.
This may suggest the use of MDIs as ﬁrst inhaler option in asthma.
Moreover, although the price of different asthma inhaler drugs is variable
between countries and depends on the agreement between manufac-
turers and health providers, MDIs are also cheaper than multi-dose DPIs.
Knowledge, belief and behavior of physicians are crucial elements of
the management and follow-up of chronic inﬂammatory disorders,
including asthma [18]. A recent survey conducted among general
practitioners (GPs, n = 811) and respiratory medicine specialists
(n = 230) investigated physician-related factors potentially contribut-
ing to asthma control failures. In this survey physicians considered
40% of asthma patients might not require continuous therapy, despite
acknowledging the role of airway inﬂammation in the pathogenesis of
disease [18]. Similar results were observed in the GAPP (Global Asthma
Physician and Patient), study, a survey based on 3559 interviews in
16 countries worldwide among physicians, adult asthma patients and
asthma nurses [19].
3. Goals of asthma management
The ﬁrst editions of the Global Initiative for Asthma (GINA) recom-
mendations evaluated asthma severity based on the clinical characteris-
tics of the patients. In the following years it became increasingly evident
that the evaluation of asthma severity must involve patient's response
to treatment. More recently, the international recommendations
suggest assessing the level of asthma control at each current patient's
level of treatment. The selection of parameters for asthma control
level assessment include daytime and nighttime symptoms, limitations
of daily activity, impairment of lung functions, and use of rescue medi-
cations. A step-up/step-down approach is recommended to achieve
these goals. This includes the dosage increase of controller medications
or the introduction of another medication in those patients where
asthma is not well controlled. Moreover, in cases of adequate disease
control, the reduction of dosage and number of medications is recom-
mended as well, to minimize adverse effects and health care costs [20].
The results of numerous randomized and controlled clinical studies
have demonstrated the efﬁcacy of using ICS/LABA (an inhaled cortico-
steroid combined with a long-acting inhaled β2-agonist) in a single
inhaler for the treatment of asthma of patients not controlled by lowdoses of inhaled steroids [21–26]. Moreover, it has been shown that
the combination of these drugs considerably improved the manage-
ment of asthma symptoms, including mild and severe exacerbations,
as compared with the administration of ICS as monotherapy [27,28].
Recently, a study was performed to evaluate the characteristics of
ICS/LABA combination therapy, considered by physicians as more
relevant for asthma treatment. GPs and specialists fromEuropean coun-
tries were asked to complete Delphi questionnaires and to take sequen-
tial surveys. At the end of this survey, a panel of experts highlighted six
main characteristics of ICS/LABA combination treatment: i) dosage
ﬂexibility (88% of attendees), ii) safety and long-term tolerability of
ICS (81%), iii) safety and long-term tolerability of LABA (81%), iv) efﬁca-
cy in asthma control (69%), v) anti-inﬂammatory power of ICS (69%), vi)
rapid bronchodilator activity of LABA (68%) [Table 1] [29].
Recently, a new combination ICS/LABA became available in the
market, developed with ﬂuticasone propionate and formoterol in three
dosages of 50/5 μg, 125/5 μg and 250/10 μg, respectively, per actuation.
4. Fluticasone propionate and formoterol
International guidelines for themanagement of asthma recommend
the administration of a LABA along with ICS when symptoms are not
well controlled using low doses of ICS monotherapy [30,31] [Fig. 1].
Combined treatmentwith ICS and LABAby a single inhaler has some ad-
vantages, in terms of pharmacology and compliance, compared with
treatments administered separately. Indeed, it had been demonstrated
that concurrent ICS and LABA can pharmacologically synergize. In clini-
cal trials ICS/LABA combination is superior to higher doses ICS on
relevant clinical outcomes [6,23,32–35], and that the use of a single
inhaler improves patient adherence to therapy and ensures that the
LABA is not taken as a single medication without the inhaled steroid
[30,33,36,37].
The choice of ICS and LABA to be combined in the same inhaler is
crucial because both ICSs and LABAs differ in terms of their speciﬁc
pharmacological proﬁles as a result of the different chemical structures
of individual agents. In the present reviewwe only discuss ICS and LABA
entering a ﬁxed ICS/LABA combination. Fluticasone propionate is one of
the most potent ICSs [35]. It has a very low oral bioavailability (≤1%)
[35] and it is well accepted that low oral availability (b10%) decreases
systemic availability and the incidence of adverse events [38]. High
receptor binding strength is correlated with high anti-inﬂammatory
activity [39]. The relative receptor-binding afﬁnity (vs dexamethasone)
of ﬂuticasone propionate is second only to mometasone [35]; however,
the inhalation half-life of mometasone is much lower than that of
ﬂuticasone propionate [35]. Being inhalation half-life a critical property
for an ICS as it relates to pulmonary retention time (i.e. the rate at
which ICSs are absorbed across the pulmonary membranes and out of
the airways) [40]. This is a disadvantage for mometasone because
longer pulmonary retention is related to prolonged efﬁcacy [40].
Moreover, ﬂuticasone propionate is the most lipophilically active ICS
[35], and therefore has a long duration of anti-inﬂammatory action. In
fact, higher lipophilicity is positively correlatedwith increased retention
in the lung and longer duration of action [38].
Controller
options***
* ICS = inhaled glucocorticosteroids 
**= Receptor antagonist or synthesis inhibitors  
As needed rapid-
acting β2-agonist As needed rapid-acting β2-agonist
Low-dose ICS plus
long-acting β2-agonist
Select one
Leukotriene
modifier**
Select one
Medium-or
high-dose ICS
Medium-or high-dose
ICS plus long-acting
β2-agonist
Low-dose ICS plus
leukotriene modifier
Low-dose ICS plus
sustained release
theophylline
To Step 3 treatment,
select one or more
To Step 4 treatment,
add either
Asthma education.  Environmental control.
(If step-up treatment is being considered for poor symptom control, first check inhaler technique, check adherence, and confirm symptoms are due to asthma.)
Low-dose inhaled
ICS*
Oral glucocorticosteroid
(lowest dose)
Anti-IgE
treatment
Leukotriene
modifier
Sustained release
theophylline
Step 2Step 1 Step 3 Step 4 Step 5
*** = Recommended treatment (shaded boxes) based on group mean data.  Individual patient needs, preferences, and circumstances  (including costs) should be considered.
Alternative reliever treatments include inhaled anticholinergics, short-acting oral β2-agonists, some long-acting β2-agonists, and short-acting theophylline.
Regular dosing with short and long-acting β2-agonists is not advised unless accompanied by regular use of an inhaled glucocorticorsteriod.
Fig. 1.Treatment steps of asthmamanagement according to guidelines GINA (reproducedwith permission) [31]. * ICS, inhaled corticosteroid. ** Receptor antagonist or synthesis inhibitors.
*** Recommended treatment (shaded boxes) based on group mean data. Individual patient needs, preferences, and circumstances (including costs) should be considered.
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effectiveness include a low oral and a high pulmonary bioavailability,
high receptor-binding afﬁnity, high protein-binding capacity and a
long pulmonary retention time [38]. Important properties for a LABA
include speed of onset of action, duration of action and agonist activity
at the β2-adrenoceptor [41]. Formoterol is the fastest acting inhaled
LABA, considerably quicker than salmeterol [42]. The duration of
bronchodilatory action of formoterol is up to 12 h, longer than that of
salbutamol and similar to that of salmeterol [43]. However, the rapid
onset of action supports the use of formoterol as a reliever medication
in addition to use in maintenance therapy [43].
Pharmacologically, the clearest distinguishing feature between β2-
agonists is the extent towhich they activate the receptor, termed intrinsic
efﬁcacy [44]. It is a key pharmacologic parameter that differs dramatically
among available β2-agonists [41]. Formoterol demonstrates high intrinsic
efﬁcacy when stimulating cyclic adenosine monophosphate (cAMP)
generation, whereas salmeterol has a much lower intrinsic efﬁcacy,
appearing as a partial agonist in all but the most highly expressed
recombinant systems [45]. Actually, in the maintenance setting,
salmeterol has a low intrinsic efﬁcacy (i.e., is a weak partial agonist,
with intrinsic efﬁcacy less than 2% relative to adrenaline), whereas
formoterol has a relatively high intrinsic efﬁcacy. It can be expected that
more severely affected patients with asthmawill show greater responses
to formoterol, whereas patients having problems with side effects might
do better with salmeterol [46]. Unfortunately, the degree of agonist-
induced desensitization of the β2-adrenoceptor also is related to agonist
efﬁcacy (strength of signaling), whereby high-efﬁcacy agonists (e.g.
formoterol) causemore phosphorylation and internalization of the recep-
tor than low-efﬁcacy agonists (e.g. salmeterol) [47].
However, high-efﬁcacy agonists do not necessarily cause more func-
tional desensitization, as was once believed [44]. It is known that partial
agonists are generallymore sensitive to the reduction of functional recep-
tors than full agonists [44,48]. In fact, low-efﬁcacy ligands are less able to
activate the receptor andmay not be sufﬁcient to generate a full response,
even when bound to all available receptors. In contrast, high-efﬁcacy ag-
onists may only need to occupy a small percentage of receptors to gener-
ate a full response, thereby leaving ‘spare receptors’ [44].4.1. Functional beneﬁts of combination therapy
The results of clinical studies conducted on ﬂuticasone propionate/
formoterol combination treatment demonstrate better efﬁcacy in terms
of improvement of respiratory function, compared with the results of
the single drugs administered asmonotherapy. The contribution of single
components in improving respiratory function has been evaluated by
assessing 1) the changes from baseline of pre-dose forced expiratory vol-
ume in 1 s (FEV1) at week 12, when comparing ﬂuticasone proprionate/
formoterol versus ﬂuticasone propionate, and 2) FEV1 changes from pre-
dose baseline to 2 h post-dose at week 12 when comparing ﬂuticasone
propionate/formoterol versus formoterol [33–35,37,49].
A new once daily ﬂuticasone furoate/vilanterol combination has been
recently approved by regulatory agencies for the use in asthma andCOPD.
It conﬁrms the superiority of ICS plus LABA over monocomponents on
relevant outcomes4.2. Therapeutic efﬁcacy and tolerability
The therapeutic efﬁcacy of the ﬂuticasone propionate/formoterol
combination has been evaluated in nine multicenter phase III clinical
studies [32–34,50–55] on patients aged ≥ 12 years [32–34,50–55] or
aged ≥18 years [32,33] with mild to moderate [53,54], moderate to
severe [32,33,50,51,55] or mild to moderate–severe persistent asthma
[34,52] [Table 2]. Further studies and pooled analyses are to be expected.
The results of the published clinical studies showed that 8–12week treat-
ment with ﬂuticasone propionate/formoterol combination in a single
inhaler, at dosages of 100/10 μg b.i.d., 250/10 μg b.i.d. and 500/20 μg
b.i.d., have shown superior clinical efﬁcacy to the same doses of the
single medications. Fluticasone proprionate/formoterol combination is
marketed at the following dosages: 50 ﬂuticasone proprionate/5 μg
formoterol, 125 ﬂuticasone proprionate/5 μg formoterol and 250
ﬂuticasone proprionate/10 μg formoterol. Two puffs b.i.d. is the recom-
mended regimen. These results were conﬁrmed by a combined data
analysis of ﬁve randomized double-blind studies, conducted in moderate
or moderate–severe asthma patients, treated for 8 weeks or 12 week
Table 2
Efﬁcacy of the combination ﬂuticasone/formoterol for the treatment of asthma patients: results of phase III clinical studies.
Study Asthma severity Patient age
(y)
Treatment
duration
(weeks)
Comparative treatment Primary endpoint Result of ﬂuticasone/
formoterol combination
[33] Moderate–severe ≥18 8 Fluticasone + formoterol or
ﬂuticasone monotherapy
Morning pre-dose FEV1 variation;
morning FEV1 pre-dose vs 2 h
post-dose FEV1
Non inferiority
[34] Mild–moderate/severe ≥12 12 Fluticasone + formoterol Morning pre–dose FEV1 vs 2 h
post–dose FEV1
Non inferiority
[32] Mild–moderate/severe ≥18 12 Fluticasone/salmeterol Morning pre-dose FEV1 variation Non inferiority
[50] Moderate–severe ≥12 12 Budesonide/formoterol Morning pre-dose FEV1 variation Non inferiority
[51] Moderate–severe ≥12 12 Fluticasone or formoterol or placebo Morning pre-dose FEV1 variation;
morning pre-dose FEV1 vs 2 h
post-dose FEV1; treatment
discontinuation due to lack
of efﬁcacy
Superiority
[52] Mild–moderate/severe ≥12 6–12 months Not applicable Safety Safe also at long term
[53] Mild–moderate ≥12 12 Fluticasone or formoterol or placebo Morning pre-dose FEV1 variation;
morning pre-dose FEV1 vs 2 h
post-dose FEV1; treatment discon-
tinuation due to lack of efﬁcacy
Superiority
[54] Mild–moderate ≥12 12 Fluticasone or formoterol Morning pre-dose FEV1 variation;
morning pre-dose FEV1 vs 2 h
post-dose FEV1
Superiority
[55] Not indicated ≥12 12 Fluticasone (two different
formulations)
Morning pre-dose FEV1 vs 2 h
post-dose FEV1
Superiority
FEV1, forced expiratory volume in 1 s.
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ular, the results of this analysis revealed that the combined administration
of ﬂuticasone propionate/formoterol at every available dosage (100/10 μg
b.i.d., 250/10 μg b.i.d. and 500/20 μg b.i.d.) showed a statistically signiﬁ-
cant superior efﬁcacy to the administration of single components, as eval-
uated by FEV1 variations at baseline pre-dose and pre-dose at the end of
the study (p b 0.001) [37,56]. The results of the combined analysis
showed that the ﬂuticasone propionate/formoterol combination in a
single dose inhaler is superior to the single components, also in terms of
tolerability. Moreover, patients treated with the combined therapy expe-
rienced a lower rate of exacerbations than those treated with ﬂuticasone
propionate (odds ratio 0.75; IC 95% 0.59–0.96) or with formoterol as
monotherapy (odds ratio 0.49; IC 95% 0.34–0.70) [37,57].
Furthermore, comparative studies performed onpatients treatedwith
ﬂuticasone propionate/formoterol combination in a single dose inhaler
versus the single components administered concurrently have shown
the non-inferiority of the combination for: 12-hours serial FEV1 area
under the curve (AUC), peak expiratory ﬂow (PEF) in morning and eve-
ning pre-dose evaluations, asthma symptom scores, percentage of
symptom-free days, quality of life (based on the Asthma Quality of Life
Questionnaire, AQLQ), mean sleep disturbance scores, and number of
uses of rescue medications. Additionally, the percentage of patients
who were discontinued due to lack of efﬁcacy of the therapy was lower
in the group treated with the ﬂuticasone/formoterol combination than
in the group of patients who concurrently received the two medications
at equivalent doses using two separate inhalers (3.9% and 7.7% respec-
tively) [37,57]. The results of efﬁcacy studies, conducted with the com-
bined administration of ﬂuticasone propionate/formoterol (100/10 μg
b.i.d., 250/10 μg b.i.d.) with ﬂuticasone propionate/salmeterol (100/50
μg b.i.d., 250/50 μg b.i.d.) have shown the non-inferiority of the former
in terms of FEV1 pre-dose baseline versus FEV1 pre-dose at week 12 of
treatment (p = 0.007) and of FEV1 pre-dose baseline versus FEV1 2 h
post-dose at week 12 of treatment (p = 0.002), in terms of PEFR, sleep
disturbance scores, rescue medication use and asthma exacerbations.
These efﬁcacy results were replicated when ﬂuticasone propionate/
formoterol and budesonide/formoterol combined therapies were com-
pared [50].
The results of clinical studies comparing ﬂuticasone propionate/
formoterol combined therapy versus i) monotherapy with single
components, ii) therapy with single components administeredconcurrently, iii) ﬂuticasone propionate/salmeterol combined therapy,
and iv) budesonide/formoterol combined therapy, showed superior ef-
ﬁcacy for the ﬂuticasone propionate/formoterol combination compared
with monotherapy with single components. Moreover, ﬂuticasone
propionate/formoterol demonstrated non-inferiority to ﬂuticasone
propionate/salmeterol or budenoside/formoterol combinations, in terms
of lung function and asthma control. However, theﬂuticasone/formoterol
combination has a more rapid bronchodilator effect than the ﬂuticasone
propionate/salmeterol combined treatment, deﬁned as the ﬁrst post-
dose measurement with FEV1 ≥ 12% of the corresponding pre-dose
value (p = 0.001) [32,37]. Moreover, the ﬂuticasone/formoterol combi-
nation is well tolerated at all considered doses [32–34,50–55], including
in long-term treatments up to 12 months [52].
The clinical efﬁcacy of an inhaler therapy is also based on the ability
of the inhaler device to provide an adequate dose of medication to the
lower respiratory tract. The drug particle size range is the main charac-
teristic of the aerosol, determining rate, distribution and the deposition
site of the medication inhaled by the airways. It has been demonstrated
that the percentage of respirable fraction contained in the aerosol
(deﬁned as drug particles with the diameter range between 2 and
5 μm) correlates with the drug deposition in lung tissues [57,58]. The
inhaler used for the administration of the ﬂuticasone propionate/
formoterol combination ensures the distribution of an aerosol with a
respirable fraction of 40% of the inhaled dose [59], which is consistent
at different inspiratory ﬂows, with a plume value of 168 ms [60].
These characteristics facilitate drug deposition throughout the airways.
The DIFFUSE study has extensively evaluated the particle size distri-
bution of the aerosol delivered by the ﬂuticasone/formoterol combina-
tion inhaler at the strength of 5/125 μg in accordance with the
European Pharmacopeia [59]. The mean (±SD) Median Mass Aerody-
namic Diameter (MMAD) and Geometric Standard Deviation (GSD)
were respectively 3.52 (±1.59) for the LABA and 3.52 (±1.56) for the
ICS at a ﬂow of 28.3 lpm; the Fine Particle Fraction (FPF) of the labeled
dose was, respectively, 39% and 41%. Further in vivo studies should
conﬁrm these results, but they suggest a good and homogeneous lung
drug distribution for both drugs. Interestingly, the ﬂuticasone propio-
nate/formoterol combination shows good consistency in proper drug
delivery at different ﬂow rates. In fact, the FPF at 60 lpm showed
percentages of 41% for the LABA and 44% for the ICS. This characteristic
may be very important as fast inhalation is one of the most common
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coordination, another common misuse of inhaler technique, may be
overcome, if necessary, using a valved holding chamber. The use of
AeroChamber Plus, which, possibly, may also contribute to increase
lung drug deposition, is suggested into the package leaﬂet of the
ﬂuticasone propionate/formoterol inhaler.
The same DIFFUSE study has compared the aerodynamics of
ﬂuticasone propionate/formoterol to that of two most commonly used
LABA/ICS combination inhalers, such as salmeterol/ﬂuticasone propio-
nate Diskus and budesonide/formoterol Turbuhaler, respectively at the
estimated equipotent strengths of 50/250 and 4/160 μg. At 60 lpm, the
optimal inhalation ﬂow with both DPIs, the MMAD, GSD and FPF of
labeled dose were, respectively, 4.0, 2.0 and 15% for salmeterol and
3.7, 1.8 and 18% with ﬂuticasone propionate. The MMAD, GSD and FPF
of labeled dose were 2.5, 1.9 and 30% with formoterol and 2.5, 1.9 and
35% with budesonide [59]. These results are substantially in accordance
with other previously known, where the average MMAD, GSD and Fine
Particle Dose of labeled dose were, respectively, 3.5, 1.5 and 18% for
salmeterol and 3.6, 1.5 and 20% with ﬂuticasone propionate using the
Diskus; and 3.3, 1.6 and 11% with formoterol and 3.1, 1.6 and 13%
with budesonide using the Turbuhaler [61].5. Conclusion and discussion
According to the recommendations of international guidelines, the
aim of asthma management is reaching stable and optimal symptom
control, improving patient quality of life, and minimizing the exacerba-
tion rates, with the consequent reduction of direct and indirect health
care costs. However, the results of many surveys among general practi-
tioners, respiratory medicine specialists and patients reveal that a large
percentage of asthma patients under treatment still have symptoms of
not well controlled disease.
Combination treatment with a LABA in addition to ICS is the main-
stay of the management of asthma, when the disease is not adequately
controlled by low dose ICS alone. The administration of ICS and LABA in
a single inhaler provides advantages in terms of pharmacology and
compliance. Indeed, the two drugs in combination synergistically
enhance the pharmacological effects of the two components. Moreover,
the use of a single inhaler device improves patient adherence to
therapy.
The results of clinical studies conducted on the ﬂuticasone propio-
nate/formoterol combination reveal that these two medications, when
administered concurrently in a single inhaler, show efﬁcacy and are
well tolerated. Symptom control and consequently quality of life of
asthma patients are improved.
The pharmacological characteristics of this combination fulﬁll the
criteria established by the main international guidelines for asthma
management, allowing the dosage ﬂexibility required by step-up and
step-down therapy.
The presence of formoterol in the combination with ﬂuticasone
propionate allows one or two inhalations per single administration,
with a wider range of ICS and LABA dosages available to the patients.
Moreover, the combination of ﬂuticasone propionate and formoterol
shares the most relevant characteristics of ICS and LABA respectively,
recommended by physicians for effective asthma management.
To date, available data suggest that the combination of the anti-
inﬂammatory effects of ﬂuticasone propionate and the rapid acting
bronchodilator effects of formoterol provides a valid treatment option
for asthma, from the point of view of both therapeutic efﬁcacy and
patient compliance.
The combination of ﬂuticasone propionate ICS and formoterol LABA
in a single inhaler for asthma treatment of adults (aged ≥12 years)
provides a valid therapeutic option in terms of efﬁcacy, patient adher-
ence to treatment and compliance to the recommendations of interna-
tional guidelines.Learning points
• The aim of asthma management is a stable and optimal symptom
control, to minimize exacerbation rates and improving patient quality
of life.
• In a large percentage of asthma patients disease is not controlled even
if under treatment.
• The combination therapy with a LABA and ICS in a single inhaler
allows one or two inhalations per single administration, providing
pharmacological and compliance advantages.
• The combination of anti-inﬂammatory ﬂuticasone and rapid-acting
bronchodilator formoterol in a single inhaler shows efﬁcacy and is
well tolerated, fulﬁlling the International Guidelines Criteria.Disclosure
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